US FDA approves Kura Oncology's blood cancer therapy

Core Insights - The U.S. Food and Drug Administration (FDA) has approved Kura Oncology's drug for treating a rare form of blood cancer that has either returned or resisted initial therapy [1] Company Summary - Kura Oncology has received FDA approval for its drug, indicating a significant milestone in its product development and potential market entry [1] Industry Summary - The approval highlights ongoing advancements in the treatment of rare blood cancers, reflecting the industry's commitment to addressing unmet medical needs [1]